drugset / Trial / NCT06008483

A Dose Finding Study to Treat Bone Tumor(s)

NCT06008483

Phase 1 Unknown 17 enrolled QSAM Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

To determine the Maximum Tolerated Dose (MTD) of CycloSam®, Samarium-153-DOTMP (Sm-153-DOTMP), a radiopharmaceutical that delivers radiation to the bone when injected, given as a tandemly administered pair of doses to subjects with one or more solid tumor(s) in the bone or metastatic solid tumors to the bone that are visible on bone scan.

Timeline

Start
2022-04-05
Primary completion
2024-04-05
Completion
2024-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject SAMARIUM DOTMP Other / unclassified 18.5 mbq/kg Other
Subject SAMARIUM DOTMP Other / unclassified 37 mbq/kg Other
Subject SAMARIUM DOTMP Other / unclassified 74 mbq/kg Other
Subject SAMARIUM DOTMP Other / unclassified 111 mbq/kg Other